Cost Curve

Three Takeaways on Drug-Pricing Policy After a Blue Wave

Plus CVS unveils plan to spin off its retail pharmacy business amidst policy pressures

Brian Reid

The Most Interesting Thing About the 2026 Election Is What the Results Will Mean for 2028

And Alnylam faces down a 340B earthquake

Brian Reid

Politicians Aren’t Really Talking Healthcare Around the Midterms, But Voters Say It’s a Critical Issue

And Medicare will pay $6 billion in illegal duplicate 340B discounts next year, IQVIA estimates

Brian Reid

New Rules Give Employers Powerful New Tools to Negotiate With PBMs

Plus thoughts on TrumpRx, GLP-1s in Medicare, and a boatload of links

Brian Reid

New Research Suggests More Seniors Than Expected Are Eligible for the CMS Bridge Program

My new publication with Sean Sullivan and Aidan Sullivan indicates 11 million American seniors could be eligible for CMS’ obesity-med pilot

Brian Reid

Republicans and Democrats Can Find Common Cause on Healthcare, a WaPo Op-Ed Argues. Hospitals Should Be Wary.

Plus thoughts on what the lack of 340B dialogue around key midterm battles says about policymaking in the new Congress

Brian Reid

Ranking 14 Would-Be Senators on the Chance They’ll Impact the Pharma Policy Debate if Elected

Brian Reid

Iowa Reveals a Hidden Truth of the 2026 Campaign: Everyone Is (Still) Gunning for PBMs

Reminder: The Cost Curve pre-election webinar is happening on Thursday

Brian Reid

Employers Paid Almost $21,000 in Premiums -- and Workers Kicked In Nearly $8K -- To Insure a Family in 2026

And our review of Senate battleground races arrives in Kansas today, where pharma topics are almost -- but not entirely -- invisible

Brian Reid